ReviewEuropean journal of medicinal chemistry2020
Potential treatment methods targeting 2019-nCoV infection.
Review in European journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.BMC infectious diseases · 2020Trial
- Article
- Development of Fluorescence-Based Assays for Key Viral Proteins in the SARS-CoV-2 Infection Process and Lifecycle.International journal of molecular sciences · 2024Review
- Design and statistical optimisation of emulsomal nanoparticles for improved anti-SARS-CoV-2 activity ofJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Graphene oxide immobilized 2-morpholinoethanamine as a versatile acid-base catalyst for synthesis of some heterocyclic compounds and molecular docking study.Scientific reports · 2023Article
- Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2.Molecules (Basel, Switzerland) · 2023Review
- Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2.European journal of medicinal chemistry · 2023Review
- A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity.Molecules (Basel, Switzerland) · 2023Review
- Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.European journal of medicinal chemistry · 2022Article
- Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation.Acta pharmacologica Sinica · 2022Article
- A rare case of drug-induced bradycardia associated with the just low dose use of methylprednisolone in a child with COVID-19.Journal of medical virology · 2022Article
- Investigational antiviral drugs for the treatment of COVID-19 patients.Archives of virology · 2022Review
- A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.Viruses · 2022Article
- Postcovid-19 Asthenic Syndrome.Neuroscience and behavioral physiology · 2022Article
- Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties.Bioorganic chemistry · 2021Article
- An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity.ChemistrySelect · 2021Review
- Kidney injury in COVID-19 patients, drug development and their renal complications: Review study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19.Genes & diseases · 2021Review
- Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2021Review
- An update review of emerging small-molecule therapeutic options for COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel coronavirus, 2019-nCoV, has quickly spread across the world and pose serious threat to public health because it can infect people very easily. The major clinical symptoms of 2019-nCoV infection include fever, dry cough, myalgia, fatigue, and diarrhea. The 2019-nCoV belongs to the betacoronavirus family, and gene sequencing results demonstrate that it is a single-stranded RNA virus, closely related to Severe Acute Respiratory Syndrome CoV (SARS-CoV) and Middle East Respiratory Syndrome CoV (MERS-CoV). It has been observed that the virus invades human body mainly through binding to angiotensin-converting enzyme 2 (ACE2) receptors similar to SARS-CoV and the main protease (Mpro) acts as a critical protease for digesting the polyprotein into functional polypeptides during the replication and transcription process of 2019-nCoV. In this review, we summarized the real-time information of 2019-nCoV treatment methods and mainly focused on the chemical drugs including lopinavir/ritonavir, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir and other potential innovative active molecules. Their potential targets, activity, clinical status and side effects are described. In addition, Traditional Chinese Medicine (TCM), Convalescent plasma therapy (CPT) and biological reagents available, as well as the promising vaccine candidates against 2019-nCoV are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.